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Similar to protein-coding genes, miRNAs are also susceptible to epigenetic modulation. Although numerous miRNAs
have been shown to be affected by DNA methylation, the regulatory mechanism of histone modification on miRNA
is not adequately understood. EZH2 and HDACs were recently identified as critical histone modifiers of deregulated
miRNAs in cancer and can be recruited to a miRNA promoter by transcription factors such as MYC. Because miRNAs
can modulate epigenetic architecture and can be regulated by epigenetic alteration, they could reasonably play an
important role in mediating the crosstalk between epigenetic regulators. The complicated network between
miRNAs and epigenetic machineries underlies the epigenetic–miRNA regulatory pathway, which is important in
monitoring gene expression profiles. Regulation of miRNAs by inducing epigenetic changes reveals promising
avenues for the design of innovative strategies in the fight against human cancer.
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MicroRNAs (miRNAs) are endogenous non-coding RNAs
(~22 nucleotides) that regulate gene expression at the
post-transcriptional level. Similar to protein-coding genes,
the expression of miRNAs is also regulated by both genetic
and epigenetic mechanisms. Approximately half of the
miRNA genes are located in fragile regions of the genome
that are associated with deletion, duplication or transloca-
tion. This suggests that alterations in miRNA genes could
be a more general defect in tumor cells [1]. With the re-
cent discovery of epigenetic processes, an increasing num-
ber of miRNAs have been discovered to be affected by
epigenetic aberrations in tumor cells [2]. Clearly, miRNA
genes can be epigenetically regulated by DNA methylation
and/or histone modifications. In turn, a subgroup of miR-
NAs, named epi-miRNAs, was recognized to directly tar-
get enzymatic effectors involved in epigenetic modulation
[3]. These observations suggest the existence of a regula-
tory circuit between epigenetic modulation and miRNAs,* Correspondence: ycao98@vip.sina.com
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stated.which could have a significant effect on transcription [4].
Because miRNAs have a large impact on carcinogenesis
through the regulation of diverse target genes, understand-
ing the regulatory mechanisms of miRNA expression is
important in treatment and prevention of human cancers.
Epigenetic changes such as DNA methylation and his-
tone modification are associated with chromatin remod-
eling and regulation of gene expression in mammalian
development and human diseases, including cancer. The
first evidence for the epigenetic regulation of miRNAs in
cancer was obtained by using chromatin modifying drugs
to reactivate miRNAs at the transcriptional level [5]. Emer-
ging evidence shows that more than one hundred miRNAs
are regulated by epigenetic mechanisms, and about one-
half of them are modulated by DNA methylation [6]. Be-
cause CpG methylation can be analyzed by a variety of
techniques with relatively high sensitivity, we can identify
miRNAs deregulated by aberrant DNA methylation in pri-
mary samples that might be limited in number and of poor
quality [7]. However, DNA methylation does not always
take place alone, but often occurs in the presence of
other epigenetic modifications, such as histone modifi-
cation, which constitutes the second major epigenetic
regulatory system of miRNAs. While DNA methylation
leads to miRNA silencing, histone modification, especiallyThis is an Open Access article distributed under the terms of the Creative
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expression, depending on the target amino acid residues
and the extent of methylation. Given that miRNA expres-
sion is tissue-specific and depends on cellular context, his-
tone modification might regulate distinct subpopulations of
miRNAs in different types of cancers. In addition, the ana-
lysis of chromatin modification status should be performed
on pure cell populations. Accordingly, identifying the spe-
cific miRNAs, which are regulated by aberrant histone
modification in clinical tissue samples, remains challenging
[8]. For the above reasons, the role of histone modification
in miRNA deregulation is still obscure and has been poorly
elucidated thus far.
In order to systematically understand the regulatory
mechanism of histone modification on miRNA expres-
sion, in this review we will focus on the current knowledge
regarding the miRNAs deregulated by epigenetic mecha-
nisms, especially histone modification, in human cancer.
We will also connect the indirect crosstalk between epi-
genetic regulators through miRNA mediation.
Epigenetic mechanisms of miRNA dysregulation
in cancer
With the progress in DNA methylation detection tech-
niques, numerous miRNAs have been identified that are
modulated by DNA methylation, shedding light on the
epigenetically regulated miRNAs. Among them, miR-9,
miR-148, miR-124, miR-137, miR-34, miR-127 and miR-
512 reportedly can be silenced by CpG hypermethylation
in at least three types of cancers [6]. However, it is still
largely unknown which miRNAs can be altered owing to
histone modifications. To date, histone methylation and
histone deacetylation were confirmed to be involved in
miRNA regulation. Understanding which and how miR-
NAs are regulated by histone modifying effectors in can-
cer might be helpful in tumor treatment.
MiR-29
The miR-29 family, which targets DNA methyltransfer-
ase 3 (DNMT3), is the first reported epi-miRNA, and is
also the most extensively studied miRNA that is regu-
lated by histone modification [9]. Recent studies show
that transcription factors can regulate miRNA expres-
sion through epigenetic mechanisms. For instance, MYC
can induce epigenetic regulation of miR-29 repression
through histone deacetylation and tri-methylation in B-cell
lymphomas (BCL), since it can recruit histone deacetylase
3 (HDAC3) and enhancer of zeste homolog 2 (EZH2) to
the miR-29 promoter, forming a MYC/HDAC3/EZH2 co-
repressor complex. Without MYC, however, the lack of
binding of HDAC3 and EZH2 to the miR-29 promoter re-
sults in increased miR-29 expression [10]. Therefore, MYC
plays an indispensable role in the epigenetic repression of
miR-29 by inducing histone deacetylation and histone tri-methylation. Meanwhile, EZH2 can also repress miR-494
to create a positive feedback loop, which in turn increases
MYC abundance and then sustains miR-29 repression in
BCL [10]. These properties indicate that different epigen-
etic modifications can cooperatively regulate the same
miRNA, whereas a specific epigenetic effector can regulate
more than one miRNAs in the same type of tumor.
Previous research evidence suggested that the tran-
scription factor Yin and yang 1 (YY-1) can recruit vari-
ous proteins such as EZH2 and HDACs to target genes
during various epigenetic events [11-13]. Later Wang et al.
confirmed that nuclear factor κB (NF-κB) up-regulated
YY-1 resulted in the recruitment of EZH2 and HDAC1 to
the miR-29 promoter in myoblasts, leading to the down-
regulation of miR-29 and maintaining cells in an undiffer-
entiated state. Once myogenesis starts, the repressive
complex containing YY-1/EZH2/HDAC will be replaced
by an activating complex. Therefore, miR-29 is restored
and in turn targets YY1 to ensure differentiation. How-
ever, the constitutively activated NF-κB–YY1 in rhabdo-
myosarcoma (RMS) could induce epigenetic repression of
miR-29 and thereby block differentiation. The inhibition
of NF-κB activity by inhibitor of nuclear factor κB α (IκBα)
would remarkably decrease the level of YY1, and conse-
quently neither EZH2 nor HDAC1 could be recruited to
miR-29 promoter [14]. This study demonstrated that NF-
κB might be an upstream regulator of the epigenetic status
of miR-29 in skeletal myogenesis.
In addition to these effects in solid tumors, miR-29 de-
regulation by epigenetic mechanisms can also be found
in human hematological cancers. For instance, in acute
myeloid leukemia (AML), the transcriptional complex NF-
κB/Sp1 can interact with HDAC1 and HDAC3 to form the
NF-κB/Sp1/HDAC complex on miR-29b enhancer, which
resulted in the silencing of miR-29b. Notably, MYC can dir-
ectly bind to miR-29b promoter and stimulate the activity
of NF-κB/Sp1/HDAC. Therefore, the down-regulation of
miR-29b is MYC-dependent [15]. Interestingly, HDAC in-
hibition could restore the expression of miR-29b in only
one third of chronic lymphocytic leukemia (CLL) samples
[16]. For the other two-thirds of CLL cases, the identifica-
tion of other histone modifications that contribute to epi-
genetic silencing of miR-29b still needs to be accomplished.
In summary, binding of MYC or NF-κB on the miR-29
promoter seems to be a primary event in miR-29 silen-
cing, and thereby induces the initial step of its chromatin
modification. Subsequently, various histone modifying en-
zymes such as EZH2 and HDACs can be recruited to the
miR-29b promoter. These enzymatic effectors might re-
ceive signals from their initiator, and then function as an
executor of this epigenetic event. Additionally, the tran-
scription factors YY1 and Sp1, which are dispensable in
this regulation, might act as bridges that connect the initi-
ator and the executor.
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Reportedly, the let-7 miRNAs, which target oncogenic Ras
and function as tumor suppressors, are located in fragile
genomic regions that are frequently deleted in human can-
cers [1,17]. Besides genomic alterations, the let-7 genes
could also be regulated by epigenetic mechanisms. MYC in-
duced by H. pylori CagA in gastric cancer cells can sup-
press the expression of let-7a and let-7c through two
epigenetic approaches: (1) MYC stimulates EZH2 expres-
sion by reducing its negative regulators, miR-26a and miR-
101; (2) MYC interacts with DNMT3B and EZH2 on the
let-7 promoter, and consequently the let-7 gene is silenced
through both DNA and histone methylation. Accordingly,
the Ras pathway is activated to contribute to carcinogenesis
[18]. However, in human lung cancers, let-7a-3 was found
to be hypomethylated, which is different from its status in
normal lung tissues [19], suggesting that differential, and
even opposite, epigenetic regulations might take place in
the same miRNA according to the cell context. In view of
that, exploration into the epigenetic modulation of the let-7
gene family is essential.
MiR-15a/miR-16 cluster
The miR-15a and miR-16 are located on the human
chromosome 13q14, and consequently their levels could
be lowered by deletions in 13q14, which occur com-
monly in CLL and mantle cell lymphoma (MCL) [20].
However, down-regulation of these two miRNAs is also
observed in many CLL cases with intact chromosome 13
[21], indicating that other mechanisms might be involved in
this regulation. Recently, HDAC inhibition was proposed to
trigger the expression of miR-15a and miR-16 in some CLL
samples, suggesting they could be epigenetically silenced by
histone deacetylation [16]. Interestingly, Zhang et al. re-
vealed that MYC repressed miR-15a/16-1 cluster expression
through recruitment of HDAC3 in MCL [22], emphasizing
that MYC plays an important role also in the epigenetic si-
lencing of the miR-15a/miR-16 cluster.
MiR-31
Like the miR-15a/miR-16 cluster, miR-31 is also consid-
ered to be both genetically and epigenetically regulated.
Genetic loss of miR-31, which resides in the deletion hot-
spot 9p21.3, was demonstrated to be beneficial for tumor
progression and was observed in several types of human
cancers [23]. However, the loss of miR-31 expression can
also be detected in tumor cells without 9p21.3 deletion.
DNA methylation and/or EZH2-mediated histone methy-
lation were recently confirmed to contribute to miR-31
loss in melanoma, breast cancer and adult T cell leukemia
(ATL) [24-26]. Also ChIP-PCR assay results revealed the
YY1 binding motifs around the miR-31 region, which re-
cruit EZH2 and mediate epigenetic silencing of miR-31.
Although YY1 could contribute to miR-31 repression,knockdown of YY1 in ATL cells without genetic deletion
only restored a small proportion of the silenced miR-31
and could not remove EZH2 completely from the miR-31
region [26]. Thus, YY1 does not appear to be indispens-
able in EZH2-mediated miR-31 silencing, pointing out the
existence of other important upstream regulators.
MiR-23a
MiR-23a was demonstrated to be transcriptionally re-
pressed by MYC in many cancer cells [27]. Besides MYC,
other transcription factors can also epigenetically regulate
miR-23a expression. For instance, the NF-κB p65 subunit
can recruit HDAC4 to miR-23a promoter, thereby silen-
cing the expression of miR-23a in human leukemic Jurkat
cells [28]. HDAC4 as a member of class IIa HDACs is
expressed tissue-specifically in heart, smooth muscle and
brain [29]. Thus, compared with the widely expressed
class I HDAC enzymes (HDAC1, -2, -3, and -8), HDAC4
seems to have a tissue-restricted role in epigenetic regula-
tion of miRNAs.
Other down-regulated miRNAs
In addition to the above miRNAs, multiple miRNAs that
are downregulated by histone modifications also exist.
For instance, miR-139-5p, miR-125b, miR-101, let-7c,
miR-200b were found to be epigenetically repressed by
EZH2, and miR-449 was repressed by HDACs in human
hepatocellular carcinoma (HCC) [30,31]. Similarly, EZH2
suppressed the expression of miR-181a, miR-181b, miR-
200b, miR-200c, let-7 and miR-203 in prostate cancer
[32,33]. Moreover, the histone demethylase Jarid1b could
also repress let-7e as well as miR-1246, miR-1826, and
miR-361-5p by removing the active mark H3K4me3 in
breast cancer [34]. However, the underlying molecular
mechanisms of these miRNAs are still unknown and
should be studied in detail.
Up-regulated miRNAs
Most of the miRNAs deregulated by aberrant patterns of
histone modification in cancer cells are silenced, but some
miRNAs, such as miR-224, miR-615 and miR-155, are ac-
tivated by histone modification.
The miR-224 is the most significantly upregulated
miRNA in HCC and was found to target apoptosis
inhibitor-5 (API-5) to promote tumorigenesis [35]. How-
ever, the regulatory mechanism of miR-224 in liver dis-
ease is mostly obscure. Actually, miR-224 overexpression
can be attributed to histone acetylation rather than gen-
omic amplification or DNA hypomethylation. The his-
tone acetylase protein EP300 acts as a positive regulator
in this regulation, whereas HDACs function as negative
regulators [36]. Considering that miR-224 overexpres-
sion could not be totally attenuated by inhibition of his-
tone acetylation, other factors might also contribute to
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cer cells identified miR-615 as an epigenetically activated
miRNA by DNA methylation loss and H3K9 acetylation
gain [37].
As an oncogenic miRNA, miR-155 is overexpressed in
many cancers such as breast cancer [38,39]. Recently,
miR-155 in normal breast tissues was proposed to be
epigenetically repressed by wild-type BRCA1, which inter-
acted with HDAC2 to deacetylate H2A and H3 on the
miR-155 promoter. In BRCA1-deficient or BRCA1-mutant
cancer cells, however, the loss or mutation of BRCA1 re-
sulted in miR-155 upregulation, since HDAC2 could not
be recruited to the miR-155 promoter [40].
The regulatory models of miR-29 and other miRNAs
suggest that the well-known transcription factor MYC,
which is one of the most commonly overexpressed on-
cogenes in cancer, has some functions in the aspect of
epigenetic regulation (Figure 1).
The crosstalk between epigenetic regulators
The importance of inhibitory signals that contribute to
epigenetic gene silencing, especially DNA methylation
and histone deacetylation, has been increasingly recog-
nized in recent years. However, the crosstalk between
these epigenetic regulators is not fully understood, be-
cause of the difficulty to apply a unique model that can
explain DNA and histone modification in specific epi-
genetic events. Nevertheless, accumulating data support
the existence of a circulation loop between DNA methy-
lation and histone modification, i.e., DNA methylation
directs histone modification and histone modificationFigure 1 A model depicting the mechanisms of histone modification
transcription factor YY1 or Sp1 on miRNA promoter, is hypothesized to be
enzymes such as EZH2 and HDACs can be recruited to methylate and deac
EZH2: MYC stimulates EZH2 expression by reducing its negative regulators,
by repressing miR-494.recruits more DNA methylation. All of these observations
suggest a reciprocal crosstalk between DNA methylation
and histone modification. Indeed, these epigenetic regula-
tors can communicate and benefit each other to reinforce
epigenetic gene silencing. In this scenario, miRNAs are
becoming a crucial factor in the faithful transmission of
different patterns of epigenetic modulation (Figure 2).
The miR-26a can be silenced by DNMTs in prostate
cancer, which induces the accumulation of its target gene
EZH2 and changes the global DNA methylation status [41],
supporting the idea that miRNAs can mediate the interplay
between epigenetic regulators. The miR-137 is another im-
portant mediator, which is silenced by promoter CpG island
hypermethylation and targets lysine-specific demethylase 1
(LSD1) in colorectal adenomas [42]. Because LSD1 can
stabilize DNMT1, a positive feedback loop exists between
them. Besides the crosstalk between DNA and histone
methylation, indirect crosstalk between DNA methylation
and histone deacetylation also occur through miRNA medi-
ation, such as miR-1 and miR-29. The miR-1, which targets
HDAC4, is down-regulated in human HCC cells because of
its CGI hypermethylation by DNMT1, thereby promoting
the expression of HDAC4 [43]. Likewise, HDACs can in-
duce miR-29 silencing in acute myeloid leukemia (AML),
which in turn increases the expression of its target gene
DNMT3 [15,44].
These findings indicate that epigenetic information can
flow from one modulation to a miRNA, and then from
the miRNA to another epigenetic pattern. As a member of
epigenetic machinery, miRNAs can also contribute to the
conversation between other epigenetic events.that repress miRNA expression. MYC or NF-κB, which interacts with
the upstream regulator of miRNA silencing. Various histone modifying
etylate histones. A positive feedback loop exists between MYC and
miR-26a and miR-101; EZH2 can also increase the abundance of MYC
Figure 2 The role of miRNAs in mediating the crosstalk between epigenetic regulators. DNMT1 contributes to miR-1 silencing in HCC cells,
thereby promoting the accumulation of its target HDAC4. The miR-29, which targets DNMT3, is down-regulated by HDACs in AML. Likewise,
miR-26a and miR-137 are silenced by promoter CpG island hypermethylation, which induces the up-regulation of the target gene LSD1 in
colorectal adenomas and EZH2 in prostate cancer.
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epigenetic drugs
The frequent dysregulation of miRNAs and their interplay
with epigenetic regulators in cancer make them attractive
biomarkers and prospective therapeutic targets in clinical
applications. The therapeutic application of miRNAs in
cancer involves two strategies: 1) inhibition of oncogenic
miRNAs by using miRNA antagonists, such as anti-miRs
or antagomiRs; or 2) introduction of tumor suppressor
miRNAs through either synthetic miRNA mimics or by
stable and vector-based transfection of genes coding for
miRNAs [45]. Moreover, a deeper understanding of these
epigenetically regulated miRNAs might lead to a novel
therapeutic strategy based on using of epigenetic drugs to
control the expression of both onco-miRNAs and tumor-
suppressor-miRNAs for prevention or treatment of hu-
man cancers.
The abnormalities of epigenetic in cancer, unlike genetic
lesions, can be reversed by epigenetic-regulated drugs,
which provides an opportunity for epigenetic therapy. The
goal of epigenetic therapy would be to target the chromatin
in rapidly dividing tumor cells in order to bring them to a
more ‘normal state’, while only mildly disturbing the epige-
nome of healthy cells [46]. Five kinds of epigenetic drugs
are known, including DNMT inhibitors, HDAC inhibitors,
histone acetyltransferase (HAT) inhibitors, histone methyl-
transferase (HMT) inhibitors and histone demethylase
(HDT) inhibitors [47]. Most of the research efforts focused
on the first two agent types. For example, two DNMT
inhibitors, 5-azacytidine (5-AzaC) and 5-aza-2′-deoxy-
cytidine (5-Aza-CdR), were approved by FDA to treat
myelodysplastic syndromes (MDS) and AML [48]. In 2006,
the FDA first approved the HDAC inhibitor suberoylani-
lide hydroxamic acid (SAHA) to treat cutaneous T-cell
lymphoma (CTCL) [49]. Probably, with the discovery and
elucidation of epigenetic–miRNA regulatory pathways, atleast part of the observed therapeutic effects of these epi-
genetic agents, such as 5-Aza-CdR, might be attributed to
their effect on miRNAs.
The deregulated miRNAs that can be controlled by
epigenetic drugs in human cancers are shown in Table 1.
These agents can either cause the re-expression of si-
lenced tumor suppressor miRNAs or repress oncogenic
miRNAs that are over- expressed in cancer cells. Besides
the most commonly used DNMT inhibitors and HDAC
inhibitors, C646 is a novel HAT inhibitor that is able to
inhibit histone acetyltransferase EP300 and suppress the
upregulated miR-224 [36]. However, these drugs might
work better together than individually. For example, the
combined use of 3-deazaneplanocin A (DZNep) and tri-
chostatin A (TSA), but not their single use, could dra-
matically induce miR-449 expression [50]. One possible
reason for this activity is that miRNA genes are regu-
lated by multiple epigenetic effectors, and thus inhibition
of one factor might not reverse miRNA expression com-
pletely. Consequently, the idea of combining different
types of epigenetic drugs to effectively control abnormal
miRNA expression in cancer cells turns out to be quite
exciting and attractive.
Conclusion
The connection between DNA methylation and histone
modification has been described in several physiological
systems and disease states. Recent investigations also ad-
ded miRNAs to this complicated crosstalk [65], thereby
reinforcing the effects of epigenetic reprogramming. A
better understanding of epigenetic regulatory mechanism
of miRNA expression will help to elucidate the complex
network of epigenetic modifications and design innovative
strategies for cancer treatment. Although DNA methyla-
tion is the best-studied epigenetic mechanism for miRNA
deregulation, it is still largely unknown which miRNAs are
Table 1 The deregulated miRNAs that can be controlled by epigenetic drugs in human cancers
Epigenetically
regulated miRNAs
Target protein Cancer type Epigenetic drug Fold change Citation
Down-regulated
miR-449 CDK6, CDC25A, c-MET Breast cancer DZNep + TSA >20 folds [50]
Hepatocellular carcinoma TSA 10-30 folds [31]
miR-125b PIGF Hepatocellular carcinoma 5-Aza-CdR >2 folds [51]
miR-126 VEGFA, PIK3R2 Bladder cancer 5-Aza-CdR + PBA >10 folds [52]
miR-127 BCL6 Bladder cancer and clear cell
renal cell carcinomas
5-Aza-CdR + PBA/TSA >10 folds [5,53]
miR-1-1 FOXP1, MET, HDAC4 Hepatocellular carcinoma 5-AzaC >20 folds [43]
miR-34 C-MYC, CDK6, Lung cancer, melanomas
and prostate cancer
5-Aza-CdR >10 folds [54,55]
miR-181a,b, miR-200a,b,c,
and miR-203
BMI1 and RING2 Prostate cancer DZNep/5-Aza-CdR/SAHA 2-20 folds [32]
miR-31 SRC, RAB27a, NIK and MET,
RhoA and WAVE3
Melanoma 5-Aza-CdR/DZNep >2 folds [24]
Breast cancer 5-Aza-CdR or 5-Aza-CdR + TSA >5 folds [25]
miR-29 Mcl-1, DNMT3A, DNMT3B,
SP1, Tcl-1, CDK6 and IGR1F
Aggressive B-Cell Lymphomas DZNep + SAHA 2-10 folds [10]
Chronic lymphocytic leukemia
and acute myeloid leukemia
LBH589/SAHA/AR-42 2-5 fold [15,16]
miR-15a/miR-16 BCL-2 and MCL-1 Chronic lymphocytic leukemia LBH589/SAHA 2-5 fold [16]
miR-205 SIP1 and ZEP Prostate cancer 5-Aza-CdR >100 folds [37]
miR-21 PDCD4, TPM1,
and MARCKS
Prostate cancer 5-Aza-CdR >2 folds [37]
miR-370 IRS-1 Oral squamous cell carcinoma 5-Aza-CdR 2-20 folds [56]
miR-373 MBD2 Hilar cholangiocarcinoma 5-Aza-CdR or 5-Aza-CdR + TSA 2-5 folds [57]
miR-193b ETS1, CCND1, PLAU Prostate cancer 5-Aza-CdR + TSA >2 folds [58]
miR-132 HB-EGF,TALIN2 Prostate cancer 5-Aza-CdR or 5-Aza-CdR + TSA >5 folds [59]
miR-145 BNIP3, TNFSF10,PAK7 Prostate cancer and clear
cell renal cell carcinomas
5-Aza-CdR or 5-Aza-CdR + TSA >2 folds [53,60]
miR-141, miR-514 HGF, CDC42,
RBX1, SLC2A1
Clear cell renal cell carcinomas 5-Aza-CdR + TSA >2 folds [53]
miR-335 SOX4, Rb1 Hepatocellular carcinoma 5-Aza-CdR + TSA >2 folds [61]
miR-205 BCL-w Prostate cancer 5-Aza-CdR 2-5 folds [62]
let-7 family RAS Nasopharyngeal carcinoma Zebularine 2-100 folds [63]
Up- regulated
miR-224 API-5 Hepatocellular carcinoma C646 <50% [36]
miR-17-92 Cluster PTEN, BCL2L11, CDKN1A Colorectal Cancer SAHA or TSA 25%-67% [64]
DNMT inhibitors: 5-azacytidine (5-AzaC); 5-aza-2′-deoxycytidine(5-Aza-CdR); Zebularine.
HDAC inhibitors: suberoylanilide hydroxamic acid (SAHA); trichostatin A (TSA); panobinostat(LBH589); phenylbutyrate (PBA); OSU-HDAC42(AR-42).
HAT inhibitors: C646.
HMT inhibitors: 3-deazaneplanocin A (DZNep).
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due to the lack of effective detection methods and rela-
tively strict requirements for obtaining and examining
clinical samples.
Notably, the expanding role of MYC in epigenetics has
recently received further attention. First, MYC can pro-
mote the expression of epigenetic enzymes, which con-
tribute to tumor development. For example, MYC can
induce the accumulation of EZH2 in prostate cancer [66].Second, recent evidence attributed the deregulated miRNA
expression to MYC, which is involved in promoting onco-
genic miRNAs and repressing tumor suppressor miRNAs
[67,68]. Considering the known mechanisms of histone
modification, MYC might function as an initiator of
miRNA epigenetic silencing, which can recruit enzymatic
effectors such as HDAC and EZH2 to the miRNA pro-
moter. Conversely, HDT and HAT are rarely reported in
miRNA regulation, pointing out the needing to evaluate
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deregulated miRNAs that contribute to carcinogenesis.
Owing to the reversible nature of epigenetic alterations,
therapeutic strategies targeting specific miRNAs based on
epigenetic intervention might provide innovative tools for
cancer treatment in the future. Further understanding of
epigenetic mechanisms in miRNA regulation along with
the effect of epigenetic drugs on specific miRNAs might
help to reset the abnormal cancer epigenome.
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